ST. LOUIS, April 29, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,314,222 titled, “Operation of a Remote Medical Navigation System Using Ultrasound Image.” The patent protects the current Spotlight feature of the Company’s Vmotion suite of automations, which enables automatic orientation of a magnetically compatible Intracardiac Echocardiography (ICE), or ultrasound, catheter to track a localized ablation catheter in conjunction with the Vdrive® system with V-Sono™ ICE catheter manipulator.
“This patent represents another important step in the expansion of our proprietary technology for enhanced treatment of arrhythmias and coronary disease,” said William C. Mills, Stereotaxis Chief Executive Officer. “The Vmotion Spotlight feature stands to positively impact both physicians and patients by improving the clinical utility of ultrasound imaging and further reducing reliance on fluoroscopy during ablation therapy delivery.”
Cleared by the FDA in June 2015, the Vmotion automation features, in combination with the V-Sono™ ICE catheter manipulator, are designed to enhance the physician’s ability to visualize, in real-time, the tip-to-tissue contact of the ablation catheter throughout a procedure using the Niobe® ES remote magnetic navigation system. As the ablation catheter moves within the heart, the Spotlight feature automatically adjusts the ICE catheter in order to keep the ablation catheter tip in its field of view. Spotlight is one of three automation features of Vmotion, which enable single-operator workflow by eliminating the need for manual ICE manipulation within the radiation field, reducing radiation exposure to the clinical team. Vmotion can also improve procedure outcomes through more exact ultrasound imaging.
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® ES remote magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its continued listing on the NASDAQ Capital Market, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
STXS Company Contact: Martin Stammer Chief Financial Officer 314-678-6155 STXS Investor Contact: Todd Kehrli / Jim Byers MKR Group, Inc. 323-468-2300 firstname.lastname@example.org